Vascular toxicity of antineoplastic agents

Nasir Shahab1, Syed Haider, Donald C Doll

  • 1Department of Medicine, Division of Hematology-Medical Oncology, Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, MO 65203, USA. shahabna@health.missouri.edu

Seminars in Oncology
|February 14, 2006
PubMed

Insights

Cancer chemotherapy can cause vascular toxicity, often overlooked due to similar symptoms from cancer or other causes. Recognizing these chemotherapy-induced vascular syndromes is crucial for patient care.

Area of Science:

  • Oncology
  • Vascular Medicine
  • Pharmacology

Background:

  • Vascular toxicity is an under-recognized adverse effect of cancer chemotherapy.
  • Symptoms of vascular toxicity can be mistaken for cancer-related complications or occur independently.
  • Cancer itself can induce a hypercoagulable state, complicating the diagnosis of treatment-related vascular events.

Purpose of the Study:

  • To review and highlight the spectrum of vascular syndromes associated with antineoplastic agents.
  • To emphasize the importance of recognizing chemotherapy-induced vascular toxicity.
  • To underscore the potential for minimizing patient morbidity and mortality through timely identification.

Main Methods:

  • Literature review of reported vascular syndromes linked to antineoplastic therapies.
  • Analysis of the range of vascular phenomena, from phlebitis to microangiopathy.
  • Synthesis of information on the attribution of vascular events to malignancy versus treatment.

Main Results:

  • Various antineoplastic therapies are associated with a range of vascular complications.
  • These complications span from superficial phlebitis to severe, life-threatening microangiopathy.
  • Vascular events are frequently under-recognized or misattributed.

Conclusions:

  • Awareness and recognition of chemotherapy-induced vascular toxicity are critical.
  • Prompt identification can lead to better management of adverse events.
  • Minimizing morbidity and preventing deaths associated with these vascular syndromes is achievable through vigilance.

Related Concept Videos

Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...